{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T06:08:26Z","timestamp":1793254106481,"version":"4.5.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jem-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Emergency Medicine"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jemermed.2021.02.020","type":"journal-article","created":{"date-parts":[[2021,3,29]],"date-time":"2021-03-29T21:04:08Z","timestamp":1617051848000},"page":"140-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies"],"prefix":"10.1016","volume":"61","author":[{"given":"Tom","family":"Knight","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6114-1956","authenticated-orcid":false,"given":"Tim","family":"Cooksley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jemermed.2021.02.020_bib1","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1001\/jama.2018.13995","article-title":"Immune checkpoint inhibitor toxicity in 2018","volume":"320","author":"Johnson","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jemermed.2021.02.020_bib2","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jemermed.2021.02.020_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jemermed.2021.02.020_bib4","doi-asserted-by":"crossref","first-page":"21","DOI":"10.52964\/AMJA.0647","article-title":"Problem-based review: immune-mediated complications of \u201cCheckpoint Inhibitors\u201d for the acute physician","volume":"16","author":"Webb","year":"2017","journal-title":"Acute Med"},{"key":"10.1016\/j.jemermed.2021.02.020_bib5","first-page":"6111","article-title":"Cancer immunotherapy-related adverse events: causes and challenges","volume":"28","author":"Blidner","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jemermed.2021.02.020_bib6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejca.2020.02.025","article-title":"Emergency presentations in patients treated with immune checkpoint inhibitors","volume":"130","author":"Cooksley","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jemermed.2021.02.020_bib7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jemermed.2018.07.005","article-title":"Management of immune checkpoint inhibitor toxicities: a review and clinical guideline for emergency physicians","volume":"55","author":"Hryniewicki","year":"2018","journal-title":"J Emerg Med"},{"key":"10.1016\/j.jemermed.2021.02.020_bib8","doi-asserted-by":"crossref","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","article-title":"The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management","volume":"2","author":"Girotra","year":"2018","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.jemermed.2021.02.020_bib9","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EC-18-0068","article-title":"Society for endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy","volume":"7","author":"Higham","year":"2018","journal-title":"Endocr Connect"},{"key":"10.1016\/j.jemermed.2021.02.020_bib11","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jemermed.2021.02.020_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jemermed.2021.02.020_bib13","first-page":"6175","volume":"28","author":"Cooksley","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jemermed.2021.02.020_bib14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jemermed.2021.02.020_bib15","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jemermed.2021.02.020_bib16","first-page":"44","article-title":"Managing thyrotoxicosis in the acute medical setting","volume":"17","author":"Napier","year":"2018","journal-title":"Acute Med"},{"key":"10.1016\/j.jemermed.2021.02.020_bib17","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jemermed.2021.02.020_bib18","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40618-020-01297-3","article-title":"Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH","volume":"44","author":"Siddiqui","year":"2021","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.jemermed.2021.02.020_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1200\/JOP.2014.001248","article-title":"Impact of observation status on hospital use for patients with cancer","volume":"11","author":"Lipitz-Snyderman","year":"2015","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.jemermed.2021.02.020_bib20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.52964\/AMJA.0755","article-title":"SAMBA18 Report \u2013 A national audit of acute medical care in the UK","volume":"18","author":"Lasserson","year":"2019","journal-title":"Acute Med"},{"key":"10.1016\/j.jemermed.2021.02.020_bib21","doi-asserted-by":"crossref","first-page":"209","DOI":"10.52964\/AMJA.0829","article-title":"Society for Acute Medicine Benchmarking Audit 2019 (SAMBA19): trends in acute medical care","volume":"19","author":"Holland","year":"2020","journal-title":"Acute Med"},{"key":"10.1016\/j.jemermed.2021.02.020_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.7861\/clinmedicine.12-6-501","article-title":"NEWSDIG: The National Early Warning Score Development and Implementation Group","volume":"12","author":"Jones","year":"2012","journal-title":"Clin Med"},{"key":"10.1016\/j.jemermed.2021.02.020_bib23","doi-asserted-by":"crossref","first-page":"R151","DOI":"10.1530\/EJE-17-0009","article-title":"Mechanisms in endocrinology: hypophysitis: diagnosis and treatment","volume":"179","author":"Joshi","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jemermed.2021.02.020_bib24","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jemermed.2021.02.020_bib25","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jemermed.2021.02.020_bib26","first-page":"3995","article-title":"Emergency ambulatory outpatient management of immune-mediated hypophysitis","volume":"28","author":"Cooksley","year":"2020","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.jemermed.2021.02.020_bib27","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S2213-8587(19)30072-5","article-title":"Checkpoint inhibitor-induced insulin-dependent diabetes: an emerging syndrome","volume":"7","author":"Perdigoto","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jemermed.2021.02.020_bib28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.jemermed.2021.02.020_bib29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/CCO.0000000000000635","article-title":"Emergency management of immune-related toxicity","volume":"32","author":"Cooksley","year":"2020","journal-title":"Curr Opin Oncol"}],"container-title":["The Journal of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467921001554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0736467921001554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:47:19Z","timestamp":1760028439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0736467921001554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0736467921001554"],"URL":"https:\/\/doi.org\/10.1016\/j.jemermed.2021.02.020","relation":{},"ISSN":["0736-4679"],"issn-type":[{"value":"0736-4679","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emergency Presentations of Immune Checkpoint Inhibitor-Related Endocrinopathies","name":"articletitle","label":"Article Title"},{"value":"The Journal of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jemermed.2021.02.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2021 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}